当前位置: X-MOL 学术Am. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma: Brown University Oncology Research Group Trial, BrUOG 324.
American Journal of Clinical Oncology ( IF 2.6 ) Pub Date : 2021-04-23 , DOI: 10.1097/coc.0000000000000820
Maria Constantinou 1 , Thomas J Miner , John M Vatkevitch , Ali Naboush , Sopha Dionson , Jasmine Anderson , Taylor Kolvek , Maria Medeiros , Kelsey MacKinnon , Roxanne Wood , Howard Safran
Affiliation  

Combined cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1 inhibitor blockade is a promising strategy in advanced melanoma and other solid tumors. This pilot study assessed the safety and toxicity of nivolumab plus low-dose ipilimumab in patients with high-risk completely resected melanoma.

中文翻译:

短程尼古鲁单抗和小剂量依匹莫单抗辅助治疗黑色素瘤的初步研究:布朗大学肿瘤学研究小组试验,BrUOG 324。

在晚期黑素瘤和其他实体瘤中,将细胞毒性T淋巴细胞相关抗原4和程序性死亡1抑制剂联用是一种有前途的策略。这项初步研究评估了尼古鲁单抗加小剂量伊立木单抗在完全切除黑色素瘤高危患者中的安全性和毒性。
更新日期:2021-04-28
down
wechat
bug